List of Excipients in Branded Drug RAPIVAB

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Seqirus USA Inc	RAPIVAB	peramivir	61364-181	HYDROCHLORIC ACID	2027-02-12
Seqirus USA Inc	RAPIVAB	peramivir	61364-181	SODIUM CHLORIDE	2027-02-12
Seqirus USA Inc	RAPIVAB	peramivir	61364-181	SODIUM HYDROXIDE	2027-02-12
Seqirus USA Inc	RAPIVAB	peramivir	61364-181	WATER	2027-02-12
BioCryst Pharmaceuticals Inc	RAPIVAB	peramivir	72769-181	HYDROCHLORIC ACID	2027-02-12

Rapivab Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Rapivab, the U.S. brand for intravenous peramivir, uses a low-complexity excipient system built around an aqueous, isotonic, preservative-free solution. The commercial opportunity is therefore less likely to come from novel excipient composition claims and more likely to come from presentation, storage, administration efficiency, pediatric dosing, hospital procurement, and regional supply resilience.

The core product is a 200 mg/20 mL single-dose vial containing peramivir at 10 mg/mL. The labeled inactive ingredient is sodium chloride, with pH adjustment using hydrochloric acid and sodium hydroxide. Each vial contains approximately 180 mg of sodium chloride, equivalent to about 71 mg of sodium. Rapivab is administered intravenously after dilution and is used for treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than two days. It is not a vaccine and is not approved for influenza prophylaxis. (U.S. Food and Drug Administration [FDA], 2014; DailyMed, 2024)

What excipients are used in Rapivab?

Rapivab has a deliberately narrow excipient profile.

Product attribute	Rapivab profile
Active ingredient	Peramivir
Dosage form	Intravenous injection
Strength	10 mg/mL
Primary presentation	200 mg/20 mL single-dose vial
Main excipient	Sodium chloride
pH adjustment	Hydrochloric acid and sodium hydroxide
Preservative	None stated in the U.S. prescribing information
Administration	Intravenous infusion after dilution
Standard adult dose	600 mg as a single dose
Vials per standard adult dose	Three 200 mg vials
Key administration issue	Hospital preparation and infusion workflow
Principal formulation risk	Stability, container compatibility, dilution compatibility, and particulate control

The formulation avoids preservatives, surfactants, complex buffers, and co-solvents. That reduces toxicological burden and simplifies manufacturing, but it also limits the number of obvious excipient-based differentiation opportunities.

Why does Rapivab use a simple sodium chloride formulation?

The formulation supports a ready-to-dilute intravenous product with limited excipient exposure. Sodium chloride provides isotonicity and is familiar to hospital pharmacy systems. Hydrochloric acid and sodium hydroxide permit pH adjustment without introducing a substantial buffer system.

The strategy has several commercial advantages:

1. It minimizes the number of inactive ingredients subject to regulatory review.
2. It reduces the risk of excipient-related hypersensitivity.
3. It supports compatibility with common hospital infusion practices.
4. It avoids preservative-related concerns for a single-dose injectable.
5. It simplifies scale-up and analytical release testing.

The same simplicity creates constraints. The product does not offer a formulation platform that can easily support multiple differentiated strengths, sustained-release versions, or device-led lifecycle extensions.

What commercial opportunities exist for Rapivab excipient and formulation development?

The strongest opportunities are presentation and workflow improvements rather than new excipient chemistry.

Ready-to-use infusion bags

The adult dose is 600 mg, which requires three 200 mg vials under the labeled presentation. A pharmacy-prepared infusion bag or manufacturer-filled premix could reduce vial manipulation, preparation time, and medication-error risk.

A commercial premix could target:

• 600 mg adult dosing;
• weight-based pediatric dosing through smaller presentations;
• emergency department use;
• hospital influenza pathways;
• government and institutional stockpiles.

The principal development issues would include container closure integrity, extractables and leachables, long-term stability, transport conditions, microbial control, and compatibility with common infusion systems.

Larger-dose vial presentations

A 600 mg vial could lower handling requirements for adult treatment. The product would need to preserve the current single-dose, preservative-free positioning while supporting accurate withdrawal and infusion preparation.

A larger vial could also reduce packaging waste. Its commercial value would depend on whether the manufacturer can demonstrate lower acquisition cost, lower pharmacy labor, or better stockpile economics.

Pediatric presentations

Pediatric treatment uses weight-based dosing and may require smaller volumes than the adult dose. Smaller vials or ready-to-use diluted presentations could improve dosing accuracy and reduce wastage.

Potential formats include:

• 100 mg or 200 mg single-dose vials;
• low-volume premixed syringes for institutional use;
• pharmacy-friendly presentations with calibrated withdrawal volumes;
• unit-dose bags for pediatric hospitals.

Pediatric lifecycle development would need to account for dosing flexibility, container hold-up volume, syringe compatibility, and the risk of concentration errors.

Improved storage and distribution stability

Influenza products face demand spikes during seasonal outbreaks and may be purchased for emergency reserves. A formulation or packaging change that extends shelf life, tolerates temperature excursions, or reduces cold-chain dependence could have procurement value.

The opportunity is commercially relevant for:

• national stockpiles;
• military and correctional-health systems;
• remote hospitals;
• disaster-response programs;
• international public-health procurement.

Any temperature-stability claim would require product-specific data. A packaging change alone would not establish a new shelf life.

What formulation patents protect Rapivab?

Rapivab’s practical formulation protection appears weaker than its active-ingredient and clinical-use protection because the marketed product relies on a conventional aqueous sodium chloride system.

A formulation patent strategy could focus on:

Potential claim area	Commercial objective	Strength assessment
Peramivir concentration range	Support alternative vial strengths	Moderate if stability data show a technical effect
pH range	Improve degradation profile	Moderate, but vulnerable if routine optimization
Buffer-free composition	Preserve low excipient burden	Narrow unless linked to unexpected stability
Premixed infusion composition	Eliminate pharmacy preparation	Potentially useful for product differentiation
Container and closure system	Control leachables and stability	Often stronger as a combination claim
Lyophilized peramivir	Improve storage or transport	Technically attractive but commercially complex
Pediatric low-volume formulation	Improve dosing accuracy	Useful if supported by human-factors or stability data
Compatible infusion combinations	Expand hospital use	Usually more vulnerable to obviousness challenges

A patent directed only to sodium chloride, pH adjustment, or a conventional aqueous peramivir solution would face a substantial obviousness risk if the claimed ranges are predictable from formulation practice. Stronger protection would require a measurable technical result, such as a defined reduction in degradation, improved container compatibility, reduced particulate formation, or a meaningful increase in storage stability.

When does Rapivab lose exclusivity?

Rapivab received FDA approval in December 2014. Its U.S. regulatory exclusivity was separate from patent protection.

Exclusivity category	Rapivab relevance
New chemical entity exclusivity	Potentially applicable depending on FDA classification at approval
New clinical investigation exclusivity	Relevant to the approval-supported clinical studies
Orphan-drug exclusivity	Not the basis of the core U.S. influenza approval
Pediatric exclusivity	Depends on completion and acceptance of FDA-requested studies
Patent term extension	Must be assessed against the patents listed for the approved product
Orange Book protection	Determined by current FDA listing and certification records

The key commercial point is that regulatory exclusivity periods tied to the 2014 approval have largely elapsed. Current entry risk depends on any remaining listed patents, statutory patent-term adjustments or extensions, regulatory filing activity, and the economic attractiveness of an injectable influenza product.

A precise current expiration analysis requires matching the approved NDA to the active Orange Book patent listings and calculating any applicable term extensions. The formulation itself is unlikely to create a long exclusivity runway unless a separately protected, commercially adopted presentation is approved.

What is the Orange Book status of Rapivab?

Rapivab is an FDA-approved small-molecule drug product regulated under NDA 206426. The FDA Orange Book is the controlling source for listed patents, pediatric information, and generic certification status. The product’s injectable status is commercially important because an ANDA applicant must demonstrate pharmaceutical equivalence, bioequivalence or an appropriate waiver, and compliance with injectable-product quality requirements. (FDA, 2024a)

For Rapivab, the principal Orange Book questions are:

• Which patents, if any, remain listed for NDA 206426?
• Are the listings directed to peramivir, the drug product, or method of use?
• Has an applicant submitted a Paragraph IV certification?
• Has the NDA holder filed a timely patent-infringement action?
• Are any listed patents subject to a 30-month stay?
• Does the proposed generic omit protected method-of-use information under a section viii statement?

Because Rapivab is administered intravenously and uses a simple composition, a generic applicant may be able to avoid formulation patents more easily than a complex biologic or modified-release product. Method-of-use patents could still affect labeling and commercial positioning.

Which companies are challenging Rapivab?

Public commercial competition is more likely to come from alternative influenza antivirals than from direct Rapivab generics.

Competitor	Company	Route	Commercial distinction
Tamiflu	Genentech/Roche	Oral	Broad prescribing familiarity and generic availability
Xofluza	Genentech/Roche	Oral, single dose	Convenient oral single-dose treatment
Relenza	GlaxoSmithKline	Inhaled	Non-oral route, with respiratory-use limitations
Generic oseltamivir	Multiple manufacturers	Oral	Lower price and broad distribution
Rapivab	BioCryst	Intravenous	Hospital-based option when oral therapy is unsuitable

No direct biosimilar pathway applies because peramivir is a chemically synthesized small molecule, not a biologic. The relevant competitive threats are abbreviated new drug applications, authorized generics, hospital purchasing substitutions, and oral antiviral products.

How strong is the Rapivab patent estate?

The patent estate is likely stronger around the active compound, manufacturing routes, and therapeutic use than around the marketed excipient system.

Active-ingredient protection

Peramivir belongs to the neuraminidase inhibitor class. Compound and synthetic-process patents may provide the strongest historical protection, but their value declines as terms expire and as alternative manufacturing routes become available.

Method-of-use protection

Potential claims may cover treatment of influenza using peramivir, specific dosing regimens, patient populations, or administration timing. Method-of-use claims can remain commercially relevant if they correspond to the FDA-approved labeling and cannot be practically carved out by a generic applicant.

Formulation protection

The marketed formulation has limited structural complexity. A formulation patent would be more defensible if it claimed a narrow combination of:

• peramivir concentration;
• defined pH;
• specified ionic strength;
• container material;
• storage condition;
• degradation threshold; and
• a demonstrated stability advantage.

Broad claims covering an aqueous peramivir solution with sodium chloride may face prior-art and obviousness challenges.

Manufacturing protection

Manufacturing patents can create practical barriers when they control a high-yield, scalable, or impurity-minimizing route. Their value depends on whether a generic manufacturer can design around the route while maintaining pharmaceutical quality and cost competitiveness.

What Paragraph IV risks exist for Rapivab?

A Paragraph IV challenge could target any unexpired Orange Book-listed patent. The most plausible strategies would be:

1. Claim invalidity based on anticipation or obviousness.
2. Noninfringement through a different formulation or manufacturing route.
3. Section viii carve-out for a protected method not included in the generic label.
4. Challenge to the scope or eligibility of a listed patent.
5. Commercial launch after a settlement or license.

For an injectable with a simple formulation, noninfringement may be more attractive than for a complex drug-delivery product. A generic applicant could use a different pH-adjusting system, container, or manufacturing process if the listed claims do not require the branded formulation.

The economic incentive for a challenge depends on influenza-season demand, hospital contracting, production scale, and the availability of oral substitutes. A generic may face limited revenue despite technical approval if seasonal utilization is low and procurement prices are compressed.

What licensing deals affect Rapivab?

Rapivab was developed by BioCryst Pharmaceuticals and has been commercialized through licensing and regional partnership arrangements. BioCryst has also used government and institutional contracting to support peramivir availability.

Licensing analysis should separate:

• U.S. commercialization rights;
• regional marketing rights;
• government procurement contracts;
• pandemic or stockpile supply agreements;
• manufacturing rights;
• rights to next-generation formulations.

The most valuable licensing opportunity is likely a formulation or supply partnership that converts the three-vial adult dose into a ready-to-use institutional presentation. A license covering only a conventional excipient composition would have weaker commercial leverage.

What manufacturing and IP barriers affect Rapivab competitors?

The main barriers are operational rather than formulation-driven.

Manufacturing barriers

Competitors must establish:

• reproducible peramivir synthesis;
• impurity control;
• sterile filling capacity;
• low-particulate injectable production;
• validated container closure systems;
• seasonal supply planning;
• stability data across distribution conditions.

A generic manufacturer may be able to avoid branded formulation claims but still face high fixed costs associated with sterile injectable manufacturing.

Supply-chain barriers

Influenza demand is seasonal and difficult to forecast. Manufacturers must hold inventory before the season, absorb expiry risk, and maintain supply during sudden outbreaks. This can discourage entry even after patent barriers decline.

Regulatory barriers

The applicant must show that the proposed product is pharmaceutically equivalent and suitable for intravenous administration. Differences in concentration, dilution instructions, packaging, or administration time could trigger additional regulatory complexity.

How does Rapivab compare with Tamiflu and Xofluza?

Rapivab has a distinct route-of-administration position but a weaker convenience profile.

Factor	Rapivab	Tamiflu	Xofluza
Active ingredient	Peramivir	Oseltamivir	Baloxavir marboxil
Route	Intravenous	Oral	Oral
Typical treatment convenience	Requires infusion	Multi-day oral course	Single oral dose
Primary setting	Hospital or supervised care	Outpatient and hospital	Outpatient and hospital
Excipient complexity	Low	Oral solid or suspension formulation	Oral tablet or granule formulation
Generic pressure	Injectable entry economics	Strong generic competition	Brand-led market
Best commercial niche	Patients unable to use oral therapy	Broad first-line use	Convenient early treatment

Rapivab’s excipient strategy supports safety and manufacturing simplicity, but its intravenous route limits routine outpatient use. Its most defensible commercial niche is patients who cannot reliably take oral therapy or who are already receiving hospital care.

What revenue exposure does Rapivab face?

Revenue exposure is tied to route substitution, seasonality, pricing, and hospital utilization rather than to excipient cost.

The principal risks are:

• replacement by generic oseltamivir;
• increased use of single-dose oral baloxavir;
• limited influenza seasons;
• hospital pharmacy budget pressure;
• low utilization outside acute-care settings;
• product expiry in stockpile and institutional inventories;
• limited opportunity to raise price through formulation innovation.

Potential revenue opportunities include:

• government preparedness contracts;
• hospital formulary placement;
• emergency-department protocols;
• pediatric institutional use;
• international supply agreements;
• ready-to-use infusion products;
• improved inventory stability.

A reformulated product could capture more value if it demonstrably lowers pharmacy labor, reduces dosing errors, or improves stockpile usability. A new excipient alone is unlikely to justify premium pricing.

Key Takeaways

• Rapivab uses a simple, preservative-free aqueous formulation based primarily on sodium chloride and pH adjustment.
• Its adult 600 mg dose requires three 200 mg vials, creating a clear opportunity for a 600 mg vial or ready-to-use infusion bag.
• Excipient patents are likely less valuable than compound, manufacturing, and method-of-use patents.
• The strongest lifecycle strategy is presentation and workflow improvement, not excipient novelty.
• Rapivab faces competition from generic oseltamivir and oral single-dose Xofluza.
• No biosimilar pathway applies because peramivir is a small-molecule drug.
• Generic entry economics may be limited by seasonal demand, sterile manufacturing costs, and hospital purchasing pressure.
• The FDA Orange Book and current Paragraph IV records control the live patent and generic-entry analysis.

FAQs

Can Rapivab be reformulated as an oral drug?

An oral reformulation would require a new formulation and clinical-development program. It would compete directly with established oral influenza antivirals and would not be a simple excipient lifecycle project.

Would a 600 mg Rapivab vial reduce hospital costs?

It could reduce vial handling and preparation labor, but the financial benefit would depend on acquisition price, stability, wastage, pharmacy workflow, and hospital dosing protocols.

Is sodium chloride the main excipient patent opportunity for peramivir?

No. A basic sodium chloride formulation would likely provide limited patent differentiation. Stronger opportunities would require a demonstrated stability, compatibility, safety, or administration benefit.

Does Rapivab have biosimilar competition?

No. Peramivir is a chemically synthesized small molecule. Competition would arise through generic-drug pathways rather than biosimilar approval.

Could a generic Rapivab avoid a method-of-use patent?

Potentially. An applicant may use a section viii statement and omit a patented indication when the remaining labeling supports a legally and clinically viable product. The outcome depends on the exact Orange Book listing and proposed label.

References

BioCryst Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://ir.biocryst.com

DailyMed. (2024). Rapivab: Peramivir injection, solution. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov

U.S. Food and Drug Administration. (2014). Rapivab prescribing information. https://www.accessdata.fda.gov

U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

U.S. Food and Drug Administration. (2024b). Abbreviated new drug application approvals and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-approvals